Oncology

Based on the results of the phase 2 ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma, Kite Pharma has submitted for, and received, a priority review for its chimeric antigen receptor (CAR)-T cell treatment, axicabtagene ciloleucel.

Amy J. Reed, MD, died 4 years following her surgery that used a power morcellator to remove her uterus, resulting in the spread of a hidden cancer.

The drug is now indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors that lack suitable alternative treatments or that have progressed on treatment.

A study published in the Annals of Internal Medicine reports that black Medicare enrollees are less likely to receive colonoscopy from more highly-rated physicians, which could increase their risk for interval colorectal cancer.

Comprehensive genetic testing using multigene testing panels for prostate cancer can arm genetic counselors with the information they need to guide precision therapy, even in men with early stage disease but a strong family history of the disease.

Although each individual rare cancer affects a small percentage of patients, the collective group of 181 rare cancers is responsible for significant disease burden in the United States.

Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology research where he anticipates significant advances will be made in coming years.

A research study by scientists at Yale and Johns Hopkins has found that surgeons are influenced by their peers when it comes to the use of new imaging technologies.

A year-long collaboration between a health consultancy and a think tank has resulted in the first draft of a framework that considers the value of healthcare services from the patient’s perspective.

The National Cancer Moonshot initiative called for tearing down the silos that prevent researchers from sharing information. FDA’s Richard Pazdur, MD, is doing just that-through the new Oncology Center of Excellence. Pazdur shares how the center will work in a special issue of Evidence-Based Oncology, publication of The American Journal of Managed Care.®

An overview of the FDA's Oncology Center of Excellence-a collaborative approach to the clinical approval process.

At the The American Journal of Managed Care®'s Spring 2017 Oncology Stakeholders Summit, the discussion touched off-label communication, the evolving clinical trial design, and healthcare reform, all while ensuring care is patient-centered.

A new study suggests that tai chi may be as effective as traditional therapies at reducing insomnia in breast cancer survivors.

Exercise is important for wellness and can also improve patient outcomes. The question remains: who should take the lead in recommending an exercise routine for patients with cancer?

A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that need treatment.

A new study indicates that a technology-based intervention could help patients make informed decisions about cancer screening.

Twenty-five percent of patients receiving neoadjuvant chemotherapy treatment for ovarian cancer develop venous thromboembolism, according to a new study published in the journal Obstetrics & Gynecology.